Belvedere Trading’s 2seventy bio TSVT Stock Holding History

Belvedere Trading’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,471	Closed	-$36.2K	–	976
2023 Q4	$36.2K	Buy	+8,471	New	+$26K	﹤0.01%	600

Other funds holding TSVT

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Belvedere Trading's TSVT Position: Q1 2024 in Review

Belvedere Trading sold out of 2seventy bio (TSVT) in Q1 2024, closing a stake of 8,471 shares — an estimated $36.2K sold.

Belvedere Trading first reported a position in TSVT in Q4 2023 and held it in 1 quarter. The position peaked at $36.2K in Q4 2023. 117 funds tracked by Wall St. Rank hold TSVT as of Q1 2024.

Belvedere Trading reported no remaining 2seventy bio position as of Q1 2024 after selling out during the quarter.
Belvedere Trading sold 8,471 2seventy bio shares in Q1 2024, an estimated $36.2K.
Belvedere Trading first reported a position in 2seventy bio in Q4 2023 and held it in 1 quarter.
Belvedere Trading's 2seventy bio position peaked at $36.2K in Q4 2023.
117 funds tracked by Wall St. Rank held 2seventy bio as of Q1 2024.

Based on Belvedere Trading's 13F filing for Q1 2024, filed 9 May 2024.